---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-010187"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:28:30.119462+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics FY2024 net loss $24.5M; cash $20.9M at year-end, ~$25M at Q1 2025

## Summary
- Net loss $24.5M for 2024 vs $11.9M in 2023, driven by $9.7M intangible impairment and $2.5M SEC settlement.
- Cash and receivables $20.9M at Dec 31, 2024, and ~$25M at end of Q1 2025; expected to fund operations into 2027.
- R&D expenses decreased to $6.1M from $7.1M; G&A expenses $11.4M (including SEC accrual).
- Enrollment in Phase 2 ovarian cancer trial expected H1 2025; VA-funded SCLC combination trial enrollment Q2-Q3 2025.
- Authorized $5M share repurchase program; ATM program fully utilized and concluded.

## SEC filing metadata
- accession: 0001437749-25-010187
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000143774925010187/0001437749-25-010187-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000143774925010187/allr20250331_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-010187
- JSON: https://secwatch.observer/filing/0001437749-25-010187.json
- Plain text: https://secwatch.observer/filing/0001437749-25-010187.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.